NCT03377101 2018-08-14Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerNational Cancer Institute (NCI)Phase 2 Withdrawn